Better Therapeutics (BTTX)
(Delayed Data from OTC)
$0.01 USD
0.00 (22.13%)
Updated May 14, 2024 02:48 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BTTX 0.01 0.00(22.13%)
Will BTTX be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BTTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BTTX
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro
BTTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jasper (JSPR) Up on FDA Nod to Begin Early-Stage Urticaria Study
Lineage (LCTX) Up 10% on Upbeat Data From Eye Disease Study
Orchard (ORTX) Up 97% on $478M Acquisition Deal With Kyowa Kirin
Other News for BTTX
12 Health Care Stocks Moving In Friday's Intraday Session
VERI, STI and VERB among mid-day movers
Geron, Graphite Bio, Immuneering among healthcare movers
Better Therapeutics Overhaul and Nasdaq Delisting
12 Health Care Stocks Moving In Friday's Pre-Market Session